Aerie Pharmaceuticals, Inc. (Aerie), has begun patient dosing in their first human clinical trial of a sustained release implant in patients with wet macular degeneration or diabetic macular edema. The polymer implant provides controlled release of AR-13503, an injectable drug that inhibits blood vessel growth in the retina, while potentially reducing the treatment burden associated […]
People who have progressed to central vision loss from any one of a number of retinal dystrophies have probably noticed a tiny spot of healthier sight in the very center of the macula (the fovea). Over time, the fovea becomes surrounded by a growing band of blindness, first appearing as individual spots, then coalescing to […]
The pronouncements are familiar. Every adult over age 40 should have a comprehensive dilated eye exam at least every three years. Every senior adult over age 65 should plan on at least every two years. But if a person has a particular condition which can affect eye health, exams should be undergone more often as […]
Leading patient advocacy organizations collaborate on important new resource Living with wet age-related macular degeneration (AMD) poses some difficult challenges, but a new free resource called “My Home in Sight Kit” can help make adapting the living space easier. Prevent Blindness has joined with five other patient advocacy organizations* to share valuable advice based upon five […]
According to the Centers for Disease Control and Intervention (CDC), “Vision impairment often co-occurs with cognitive decline, which can be associated with functional limitations”. Data from Analysis of 2015–2017 Behavioral Risk Factor Surveillance System determined that, “after adjusting for age and other demographic and smoking characteristics, 18% of adults who reported vision impairment also reported […]
It was reported here in March 2017 that BioTime, Inc. is conducting a Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. OpRegen is a retinal pigment epithelium (RPE) stem cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). RPE cells are essential […]
Reprinted courtesy of Laramy-K Optical Lab It is an all too common misconception that yellow tinted or yellow polarized night driving glasses are beneficial for night time driving. The thought is, the yellow or amber color reduces glare and improves contrast. However, in reality, when driving at night or dusk in already limited lighting conditions, […]
(Updated 7/29/19) Age-related macular degeneration (AMD) is a progressive disease of the retina wherein the light-sensing cells in the central area of vision (the macula) stop working and eventually die. The disease is thought to be caused by a combination of genetic and environmental factors, and it is most common in people who are age […]
After years of intensive public education efforts about the causes and symptoms of a mysterious hallucinatory condition affecting visually impaired people, Prevent Blindness and other patient advocacy organizations are pleased that Charles Bonnet Syndrome will soon be officially recognized by eye care professionals around the world. As described in the latest revision of the International […]
This is our 14th annual summary presented to the International Low Vision Support Group about leading research and developments during the past 12 months in the fields of blindness and low vision. Most activity has been in the fields of anti-VEGF treatment and gene replacement therapy. We have also seen promising work with stem cell […]